Small cell lung cancer (SCLC) transformation is seen in approximately 3% to 14% of NSCLC cases after first line EGFR TKI treatment.[4,6] In such cases, cytotoxic drugs are commonly used according to the histologic findings. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.